2021
DOI: 10.1128/mbio.00765-21
|View full text |Cite
|
Sign up to set email alerts
|

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma

Abstract: Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but the antibody characteristics that contribute to efficacy remain poorly understood. This study analyzed plasma samples from 126 eligible convalescent blood donors in addition to 15 naive individuals, as well as an additional 20 convalescent individuals as a validation cohort. Multiplexed Fc Array binding assays and functional antibody response assays were utilized to evaluate severe acute respiratory syndrome coronavirus 2 (… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
69
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1
1

Relationship

3
7

Authors

Journals

citations
Cited by 68 publications
(72 citation statements)
references
References 85 publications
0
69
0
Order By: Relevance
“…At present, analyses of Fc-mediated functions of SARS-CoV-2 antibodies within COVID-19 convalescent subjects have focused upon cross-sectional analyses or short-term longitudinal studies up to 1 to 2 months post-symptom onset. 16,19,20 We extend these findings and analyze Fc effector functions mediated by S-specific antibodies in a cohort of 53 convalescent individuals up to 149 days postsymptom onset. We developed functional assays using SARS-CoV-2 S-expressing cells to comprehensively analyze plasma ADCC and ADP activity against SARS-CoV-2 S. Our results show that plasma ADCC and ADP activity decays over the first 4 months post-infection, mirroring the decline in S-specific IgG titers.…”
Section: Introductionmentioning
confidence: 78%
“…At present, analyses of Fc-mediated functions of SARS-CoV-2 antibodies within COVID-19 convalescent subjects have focused upon cross-sectional analyses or short-term longitudinal studies up to 1 to 2 months post-symptom onset. 16,19,20 We extend these findings and analyze Fc effector functions mediated by S-specific antibodies in a cohort of 53 convalescent individuals up to 149 days postsymptom onset. We developed functional assays using SARS-CoV-2 S-expressing cells to comprehensively analyze plasma ADCC and ADP activity against SARS-CoV-2 S. Our results show that plasma ADCC and ADP activity decays over the first 4 months post-infection, mirroring the decline in S-specific IgG titers.…”
Section: Introductionmentioning
confidence: 78%
“…This more restrictive functional antibody response failed to protect in clinical trials [ 8 ]. Polyfunctional antibody responses are likely to be important for the prevention and control of other viral infections, including, for example, HIV, Ebolavirus and SARS-CoV-2 [ 32 , 33 , 34 , 35 ]. We speculate that prophylactic and therapeutic vaccines that elicit polyfunctional responses will prove more effective in preventing HSV and other viral infections.…”
Section: Discussionmentioning
confidence: 99%
“…Antibody functions, including neutralization assessed by either an authentic virus assay or a luciferase-based pseudovirus assay, antibody-dependent cell-mediated phagocytosis (ADCP) mediated by monocytes, deposition of the complement cascade component C3b (ADCD), and FcgRIIIa ligation as a proxy for NK cell mediated antibody dependent cellular cytotoxicity (ADCC) induced by antibodies in response to recombinant antigen were previously reported 26 for a set of convalescent samples collected from a discovery cohort of 126 eligible convalescent plasma donors from the Baltimore/Washington D.C. area (Johns Hopkins Medical Institutions, JHMI) 27 and serum samples from 15 naïve controls and a validation cohort of 20 convalescent subjects from New Hampshire (Dartmouth-Hitchcock Medical Center, DHMC) 43 (Supplemental Table 1). Biophysical antibody features were defined by a customized multiplexed Fc array assay that characterizes both variable fragment (Fv) and Fc domain attributes across a panel of SARS-CoV-2 antigens, consisting of: nucleocapsid (N) protein, stabilized (S-2P) 44 and unstabilized trimeric spike protein, spike subdomains including S1 and S2, the receptor binding domain (RBD), and the fusion peptide (FP) from SARS-CoV-2; in addition, the panel included diverse pathogenic, zoonotic, and endemic coronavirus spike proteins and subdomains.…”
Section: Characterization Of Antibody Responses Following Sars-cov-2 Infectionmentioning
confidence: 99%